Summary
- JNJ continues to face negative news headlines regarding talc powder issues.
- In recent years, these concerns have led to sell-offs, and late last week when news broke of a criminal probe from the DoJ, we got another.
- JNJ shares are currently trading for ~16x TTM earnings. My next buy target is 15x.
- This idea was discussed in more depth with members of my private investing community, The Dividend Growth Club . Start your free trial today ยป
The healthcare sector had a rough couple of days at the end of last week, as news regarding the Trump administration's new stance on the status of rebates collected by pharmacy benefit managers. This is yet another bit of negative political news for the drug makers, adding to the fear surrounding this space as we creep closer to the 2020 election where healthcare reform will most definitely be a major issue. And, on top of it all, on Friday news broke that the DOJ was launching a criminal probe focused on Johnson & Johnson's (NYSE:JNJ) talc powder/asbestos issues. This caused JNJ's losses to accelerate, and although the company bounced off of the intra-day lows a bit, shares still closed the week at their lowest levels since early June.
Anytime a dividend aristocrat like JNJ sells off, my ears perk up a bit. This is a high-quality company that has been generating massive wealth for shareholders for decades now. It's a core-type buy-and-hold position for many dividend growth investors and now that shares are nearing recent support levels, I wanted to take a closer look at the stock.
First and foremost, I think it's worth noting that these talc powder issues have been ongoing for a while now, and I don't think they're going to disappear anytime soon. We've seen numerous court decisions in recent years regarding talc and cancer, and there certainly hasn't been a consensus in the courts. JNJ has won cases and it's lost cases. The company has gone to appeal and won there as well. If you're looking for an article with a hot take on this issue and how to trade the stock based off of it, then you should probably stop reading now. Instead, I'm maintaining the sentiment that JNJ remains a blue-chip stock that should provide a safe dividend and slow and steady growth over the long term, regardless of what the major headlines appear to signal.
Second, I think it's also important to note that this DOJ news shouldn't have been a major surprise to shareholders. As JNJ representatives said in this Reuters piece published Friday, JNJ had already disclosed subpoenas from the DOJ in its February 2019 SEC filings. Honestly, I'm both surprised and disappointed in the market for the 5% move that this old news sparked on Friday. This should have already been priced into the stock. The most recent bout of weakness looks like a fear-driven move to me.
Frankly put, I'm not a lawyer, and I don't claim to have an informed opinion when it comes to the viability of the accusations that JNJ faces, how quickly this issue is going to be resolved, and what the ultimate financial impact may be on the company. I'm not sure that anyone does. Heck, this government probe could end up totally exonerating JNJ and turn out to be a positive for the stock. All I know is that Johnson & Johnson's legal team has proven itself to be very capable of defending this company in the court room up until now and anyone buying into this name has to have a certain level of faith in its management team, as well as its lawyers, moving forward.
With regard to this faith in leadership, I have it. I've said this before, and I'm sure I'll say it again; excellence doesn't happen on accident. Companies don't rise to the level of success and prominence that JNJ holds without top-notch leadership that cultivates a culture that allows talent to thrive. JNJ is a $350b market cap company with a strong portfolio of products and one of the most attractive pipelines in the big-pharma/biopharma space. This is one of just two companies in the world that has a AAA-rated balance sheet (Microsoft (MSFT) is the other) showing that JNJ's management team has been an outstanding steward of capital. For comparison's sake, the U.S. government's credit rating is lower, at AA+. I know this is a rather simplistic stance, but as a shareholder, I'm willing to trust the same management that built this behemoth of a company and curated this best-in-class balance sheet to steer through these tumultuous waters as well.

